Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes

Xenobiotica

Volumn 28, Issue 2, 1998, Pages 103-115

  Yamazaki, H ^a   Inoue, K ^a   Shimada, T ^a  

^a OSAKA PREFECTURAL INSTITUTE OF PUBLIC HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; LIVER ENZYME; RECOMBINANT ENZYME; SULFAPHENAZOLE; TOLBUTAMIDE; WARFARIN;

ALLELE; AMINO ACID SEQUENCE; ARTICLE; CONTROLLED STUDY; DRUG HYDROXYLATION; DRUG OXIDATION; ENZYME INHIBITION; ENZYME KINETICS; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; LIVER MICROSOME; RACEMIC MIXTURE;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; GENOTYPE; HUMANS; HYDROXYLATION; JAPAN; KINETICS; MICROSOMES, LIVER; POLYMORPHISM, GENETIC; RECOMBINANT PROTEINS; STEREOISOMERISM; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; SULFAPHENAZOLE; TOLBUTAMIDE; WARFARIN;

EID: 0031912544     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/004982598239614     Document Type: Article

References (40)

1. BRIAN, W. R., SRIVASTAVA, P. K., UMBENHAUER, D. R., LLOYD, R. S. and GUENGERICH, F. P., 1989, Expression of a human liver cytochrome P-450 protein with tolbutamide hydroxylase activity in Saccharomyces cerevisiae. Biochemistry, 28, 4993-4999.
2. DE MORAIS, S. M. F., WILKINSON, G. R., BLAISDELL, J., MEYER, U. A., NAKAMURA, K. and GOLDSTEIN, J. A., 1994, Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Molecular Pharmacology, 46, 594-598.
3. GOLDSTEIN, J. A. and DE MORAIS, S. M. F., 1994, Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics, 4, 285-299.
4. GONZALEZ, F. J., 1989, The molecular biology of cytochrome P450s. Pharmacological Reviews, 40, 243-288.
5. GONZALEZ, F. J., CRESPI, C. L. and GELBOIN, H. V., 1991, cDNA-expressed human cytochrome P450s: a new age of molecular toxicology and human risk assessment. Mutation Research, 247, 113-127.
6. GONZALEZ, F. J. and KORZEKWA, K. R., 1995, Cytochromes P450 expression systems. Annual Reviews of Pharmacology and Toxicology, 35, 369-390.
7. GUENGERICH, F. P., 1991, Reactions and significance of cytochrome P-450 enzymes. Journal of Biological Chemistry, 266, 10019-10022.
8. GUENGERICH, F. P., 1994, Analysis and characterization of enzymes. In Principles and Methods of Toxicology, edited by A. W. Hayes (New York: Raven), pp. 1259-1313.
9. GUENGERICH, F. P., BRIAN, W. R., SARI, M.-A. and ROSS, J. T., 1991, Expression of mammalian cytochrome P450 enzymes using yeast-based vectors. Methods in Enzymology, 206, 130-145.
10. GUENGERICH, F. P., GILLAM, E. M. J. and SHIMADA, T., 1996, New applications of bacterial systems to problems in toxicology. Critical Reviews in Toxicology, 26, 551-583.
11. GUENGERICH, F. P. and SHIMADA, T., 1991, Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chemical Research in Toxicology, 4, 391-407.
12. GUENGERICH, F. P., WANG, P. and DAVIDSON, N. K., 1982, Estimation of isozymes of microsomal cytochrome P-450 in rats, rabbits, and humans using immunochemical staining coupled with sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Biochemistry, 21, 1698-1706.
13. HAINING, R. L., HUNTER, A. P., VERONESE, M. E., TRAGER, W. F. and RETTIE, A. E., 1996, Allelic variants of human cytochrome P4502C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Archives of Biochemistry and Biophysics, 333, 447-458.
14. INOUE, K., YAMAZAKI, H., IMIYA, K., AKASAKA, S., GUENGERICH, F. P. and SHIMADA, T., 1997, Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4′-hydroxylation activities in livers of Japanese and Caucasian populations. Pharmacogenetics, 7, 103-113.
15. KAMINSKY, L. S., FASCO, M. J. and GUENGERICH, F. P., 1981, Production and application of antibodies to rat liver cytochrome P-450. Methods in Enzymology, 74, 262-272.
16. KAMINSKY, L. S., DE MORAIS, S. M. F., FALETTO, M. B., DUNBAR, D. A. and GOLDSTEIN, J. A., 1993, Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. Molecular Pharmacology, 43, 234-239.
17. KNODELL, R. G., HALL, S. D., WILKINSON, G. R. and GUENGERICH, F. P., 1987, Hepatic metabolism of tolbutamide: characterization of the form of cytochrome P-450 involved in methyl hydroxylation and relationship to in vivo disposition. Journal of Pharmacology and Experimental Therapeutics, 241, 1112-1119.
18. LANG, D. and BÖCKER, R., 1995, Highly sensitive and specific high-performance liquid chromatographic analysis of 7-hydroxywarfarin, a marker for human cytochrome P-4502C9 activity. Journal of Chromatography B: Biomedical Applications, 672, 305-309.
19. LOPEZ-GARCIA, M. P., DANSETTE, P. M., VALADON, P., AMAR, C., BEAUNE, P. H., GUENGERICH, F. P. and MANSUY, D., 1993, Human-liver cytochromes P-450 expressed in yeast as tools for reactive-metabolite formation studies. Oxidative activation of tienilic acid by cytochromes P-450 2C9 and 2C10. European Journal of Biochemistry, 213, 223-232.
20. LOWRY, O. H., ROSEBROUGH, N. J., FARR, A. L. and RANDALL, R. J., 1951, Protein measurement with the Folin phenol reagent. Journal of Biological Chemistry, 193, 265-275.
21. MIMURA, M., BABA, T., YAMAZAKI, H., OHMORI, S., INUI, Y., GONZALEZ, F. J., GUENGERICH, F. P. and SHIMADA, T., 1993, Characterization of cytochrome P450 2B6 in human liver microsomes. Drug Metabolism and Disposition, 21, 1048-1056.
22. NELSON, D. R., KOYMANS, L., KAMATAKI, T., STEGEMAN, J. J., FEYEREISEN, R., WAXMAN, D. J., WATERMAN, M. R., GOTOH, O., COON, M. J., ESTABROOK, R. W., GUNSALUS, I. C. and NEBERT, D. W., 1996, P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 6, 1-42.
23. OMURA, T. and SATO, R., 1964, The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. Journal of Biological Chemistry, 239, 2370-2378.
24. RETTIE, A. E., KORZEKWA, K. R., KUNZE, K. L., LAWRENCE, R. F., EDDY, A. C., AOYAMA, T., GELBOIN, H. V., GONZALEZ, F. J. and TRAGER, W. F., 1992, Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chemical Research in Toxicology, 5, 54-59.
25. RETTIE, A. E., WIENKERS, L. C., GONZALEZ, F. J., TRAGER, W. F. and KORZEKWA, K. R., 1994, Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics, 4, 39-42.
26. ROMKES, M., FALETTO, M. B., BLAISDELL, J. A., RAUCY, J. L. and GOLDSTEIN, J. A., 1991, Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. Biochemistry, 30, 3247-3255.
27. SANDHU, P., BABA, T. and GUENGERICH, F. P., 1993, Expression of modified human cytochrome P450 2C10 (2C9) in Escherichia coli, purification, and reconstitution of catalytic activity. Archives of Biochemistry and Biophysics, 306, 443-450.
28. SHIMADA, T., IWASAKI, M., MARTIN, M. V. and GUENGERICH, F. P., 1989, Human liver microsomal cytochrome P-450 enzymes involved in the bioactivation of procarcinogens detected by umu gene response in Salmonella typhimurium TA1535/pSK1002. Cancer Research, 49, 3218-3228.
29. SHIMADA, T., MISONO, K. S. and GUENGERICH, F. P., 1986, Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction. Journal of Biological Chemistry, 261, 909-921.
30. SHIMADA, T., YAMAZAKI, H., MIMURA, M., INUI, Y. and GUENGERICH, F. P., 1994, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. Journal of Pharmacology and Experimental Therapeutics, 270, 414-423.
31. SPIELBERG, S., MCCREA, J., CRIBB, A., RUSHMORE, T., WALDMAN, S., BJOMSSON, T., LO, M.-W. and GOLDBERG, M., 1996, A mutation in CYP2C9 is responsible for decreased metabolism of losartan. Clinical Pharmacology and Therapeutics, 59, 215.
32. 359 allelic variant in the tolbutamide polymorphism. Pharmacogenetics, 6, 341-349.
33. TRACY, T. S., ROSENBLUTH, B. W., WRIGHTON, S. A., GONZALEZ, F. J. and KORZEKWA, K. R., 1995, Role of cytochrome P450 2C9 and an allelic variant in the 4′-hydroxylation of (R)-and (S)-flurbiprofen. Biochemical Pharmacology, 49, 1269-1275.
34. VERONESE, M. E., DOECKE, C. J., MACKENZIE, P. I., MCMANUS, M. E., MINERS, J. O., REES, D. L., GASSER, R., MEYER, U. A. and BIRKETT, D. J., 1993, Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochemical Journal, 289, 533-538.
35. WANG, S. L., HUANG, J. D., LAI, M. D. and TSAI, J. J., 1995, Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics, 5, 37-42.
36. YAMAZAKI, H., GUO, Z., PERSMARK, M., MIMURA, M., INOUE, K., GUENGERICH, F. P. and SHIMADA, T., 1994, Bufuralol hydroxylation by cytochrome P450 2D6 and 1A2 enzymes in human liver microsomes. Molecular Pharmacology, 46, 568-577.
37. YAMAZAKI, H., INOUE, K., TURVEY, C. G., GUENGERICH, F. P. and SHIMADA, T., 1997, Effects of freezing, thawing, and storage of human liver samples on the microsomal contents and activities of cytochrome P450 enzymes. Drug Metabolism and Disposition, 25, 168-174.
38. 5 in the oxidation of testosterone and nifedipine by recombinant cytochrome P450 3A4 and by human liver microsomes. Archives of Biochemistry and Biophysics, 325, 174-182.
39. YASUMORI, T., YAMAZOE, Y. and KATO, R., 1991, Cytochrome P-450 human-2 (P-450IIC9) in mephenytoin hydroxylation polymorphism in human livers: differences in substrate and stereoselectivities among microheterogeneous P-450IIC species expressed in yeasts. Journal of Biochemistry, 109, 711-717.
40. ZHANG, Z., FASCO, M. J., HUANG, Z., GUENGERICH, F. P. and KAMINSKY, L. S., 1995, Human cytochromes P4501A1 and P4501A2: R-warfarin metabolism as a probe. Drug Metabolism and Disposition, 23, 1339-1345.